

# Maria Di Bartolomeo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6202121/maria-di-bartolomeo-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185  
papers

6,941  
citations

40  
h-index

79  
g-index

195  
ext. papers

8,592  
ext. citations

5.5  
avg, IF

5.01  
L-index

#	Paper	IF	Citations
185	Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 29, 3096	3.1	2
184	ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 29, 3111	3.1	1
183	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , <b>2022</b> , 27, e29-e36	5.7	0
182	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 449-462	59.2	30
181	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 780716	5.3	1
180	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e220290	10.4	0
179	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102583	2.2	4
178	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100472	3.6	0
177	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 100-111	7.5	1
176	Tumors of the Small Intestine, Colon, and Rectum. <i>Pediatric Oncology</i> , <b>2022</b> , 223-244	0.5	
175	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2200015	3.6	2
174	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors <b>2021</b> , 9,		5
173	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 1749-1759	3.6	
172	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 190-201	7.5	0
171	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 779-789	21.7	53
170	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 161-169	4.9	3
169	Tremellimumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7

168	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 2315-2324	3.6	0
167	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , <b>2021</b> , 107, 150-159	1.7	2
166	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 4-10	3.6	5
165	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , <b>2021</b> , 26, 302-309	5.7	4
164	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 31-40	7.5	5
163	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 3971-3980	3.9	3
162	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3126-3140	12.9	6
161	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2505-2514	12.9	3
160	Target therapies plus somatostatin analogs in NETs: a network meta-analysis. <i>Endocrine-Related Cancer</i> , <b>2021</b> , 28, 467-479	5.7	0
159	Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	5
158	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , <b>2021</b> , 1	7.6	8
157	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , <b>2020</b> , 25, 803-809	5.7	17
156	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. <i>Gastric Cancer</i> , <b>2020</b> , 23, 1064-1074	7.6	4
155	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 230-239	7.5	6
154	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , <b>2020</b> , 25, e460-e468	5.7	13
153	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1017-1024	12.9	8
152	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 161-173	7.1	4
151	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , <b>2020</b> , 25, e928-e935	5.7	5

150	One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. <i>World Journal of Gastrointestinal Oncology</i> , <b>2020</b> , 12, 833-849	3.4	5
149	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 156-164	3.8	12
148	Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: Impact of anatomical site of pelvic recurrence on long-term results. <i>Surgical Oncology</i> , <b>2020</b> , 35, 89-96	2.5	4
147	Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
146	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
145	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820927271	4.7	3
144	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , <b>2020</b> , 25, 780-786	5.7	5
143	Gastric cancer: Translating novel concepts into clinical practice. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 79, 101889	14.4	39
142	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3099-3110	2.2	35
141	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3392-3400	2.2	123
140	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 420-435	21.7	110
139	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 465-472	3.5	11
138	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 183-191.e3	3.8	11
137	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , <b>2019</b> , 97, 38-43	3.6	14
136	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 849-861	21.7	201
135	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 2858	4.9	26
134	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , <b>2019</b> , 9, 3545	4.9	18
133	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e179-e190	3.8	7

132	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , <b>2019</b> , 11,	6.6	45
131	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , <b>2019</b> , 19, 283	4.8	8
130	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 1-7	7.5	6
129	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 125-132.e2	3.8	23
128	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , <b>2019</b> , 15, 3015-3024	3.6	0
127	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1268-1275	13.4	37
126	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 66-66	2.2	15
125	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , <b>2019</b> , 24, 385-393	5.7	15
124	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	17
123	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-11	3.6	
122	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 164-174	7.5	6
121	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 34-43.e6	3.8	5
120	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 72, 45-55	14.4	51
119	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. <i>Tumori</i> , <b>2019</b> , 105, 113-120	1.7	4
118	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2276-2284	12.9	25
117	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e457-e470	3.8	14
116	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , <b>2018</b> , 13, 227-234	5	23
115	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 607-618	5.7	13

114	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1394-1401	10.3	47
113	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1047-1068	2.6	9
112	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , <b>2018</b> , 13, 567-582	5	11
111	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , <b>2018</b> , 95, 344-352	3.6	9
110	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1800-1806	10.3	22
109	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2018</b> , 392, 123-133	40	624
108	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5-5	2.2	18
107	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1082-1089	12.9	58
106	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1478-1485	2.2	41
105	Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. <i>Tumori</i> , <b>2018</b> , 104, NP10-NP13	1.7	2
104	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , <b>2018</b> , 23, 1178-1187	5.7	31
103	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 224-231	3.5	6
102	Gastrointestinal tract carcinoma in pediatric and adolescent age: The Italian TREP project experience. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26658	3	14
101	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, 148-163	2.8	54
100	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. <i>Oncology</i> , <b>2017</b> , 93, 279-286	3.6	8
99	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 347-352	8.7	22
98	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5671-5678	12.9	91
97	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2414-2422	12.9	111

96	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, e191-e198	3.8	9
95	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 834-845	5.2	9
94	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 24-8	7	16
93	Osteopontin, E-cadherin, and Eatenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , <b>2016</b> , 19, 412-420	7.6	25
92	Toward the molecular dissection of peritoneal pseudomyxoma. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2097-2103	10.3	45
91	Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2074-2081	10.3	33
90	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 963-71	24.4	71
89	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 125	8.5	26
88	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , <b>2016</b> , 11, 337-43	5	18
87	Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. <i>Tumori</i> , <b>2016</b> , 102, e15-9	1.7	10
86	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 2859-2864	7.5	57
85	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 1467-74	7.5	25
84	In reply. <i>Oncologist</i> , <b>2015</b> , 20, e5	5.7	1
83	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 473-481	7.5	12
82	Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 8884-95	6.3	13
81	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 272-81	7	13
80	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2092-7	10.3	110
79	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 800-7	7.5	40

78	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 581-8	3.8	41
77	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , <b>2015</b> , 20, 1261-5	5.7	29
76	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 315-21	5.3	24
75	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , <b>2015</b> , 10, 127-33	4	1
74	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 96, 156-66	7	50
73	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , <b>2015</b> , 32, 182	3.7	18
72	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 2069-81	2.6	13
71	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 587-94	7.5	329
70	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , <b>2014</b> , 25, 404-8	10.3	51
69	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , <b>2014</b> , 9, e92147	3.7	17
68	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. <i>Cancers</i> , <b>2014</b> , 6, 1753-68	6.6	13
67	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , <b>2014</b> , 19, 845-50	5.7	37
66	TP53 mutations in advanced colorectal cancer: the dark side of the moon. <i>Oncology</i> , <b>2014</b> , 86, 289-94	3.6	8
65	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1373-1378	10.3	61
64	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e581	21.7	1
63	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 1223-37	3.8	32
62	Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2014</b> , 37, 545-9	2.7	8
61	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e108940	3.7	46

60	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , <b>2014</b> , 9, 155-62	5	23
59	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , <b>2014</b> , 2, 835-9	1.6	21
58	Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 4516-25	5.6	23
57	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , <b>2013</b> , 30, 610	3.7	7
56	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , <b>2013</b> , 15, 582-6	3.6	2
55	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. <i>Oncology</i> , <b>2013</b> , 84, 191-9	3.6	27
54	Role of cMET in the development and progression of colorectal cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 18056-77	6.3	38
53	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 1098-103	4.6	22
52	A review on biomarkers for prediction of treatment outcome in gastric cancer. <i>Anticancer Research</i> , <b>2013</b> , 33, 1257-66	2.3	48
51	Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. <i>Translational Oncology</i> , <b>2012</b> , 5, 155-9	4.9	13
50	Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab. <i>Medical Oncology</i> , <b>2012</b> , 29, 2838-41	3.7	3
49	A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. <i>Cancer</i> , <b>2012</b> , 118, 4132-8	6.4	11
48	Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. <i>Drugs and Aging</i> , <b>2011</b> , 28, 83-91	4.7	1
47	Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report. <i>Tumori</i> , <b>2010</b> , 96, 154-156	1.7	7
46	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1729-37	27.4	586
45	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , <b>2009</b> , 20, 84-90	10.3	327
44	Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 67-72	3.5	6
43	Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1842-7	10.3	419

42	Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 439-44	8.7	33
41	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1810-6	10.3	28
40	Pathological features as predictors of recurrence after radical resection of gastric cancer. <i>British Journal of Surgery</i> , <b>2006</b> , 93, 205-9	5.3	32
39	Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. <i>Oncology</i> , <b>2006</b> , 71, 341-6	3.6	11
38	Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition. <i>Tumori</i> , <b>2006</b> , 92, 379-383	1.7	10
37	Capecitabine chemoradiation for rectal cancer after curative surgery. <i>Journal of Chemotherapy</i> , <b>2006</b> , 18, 85-9	2.3	6
36	A Modified Prognostic Score for Patients with Curatively Resected Gastric Cancer. <i>Tumori</i> , <b>2005</b> , 91, 221-226	1.7	4
35	A modified prognostic score for patients with curatively resected gastric cancer. <i>Tumori</i> , <b>2005</b> , 91, 221-6	1.7	4
34	Raltitrexed plus Oxaliplatin in the Treatment of Metastatic Colorectal Cancer. <i>Tumori</i> , <b>2004</b> , 90, 186-191	1.7	7
33	Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. <i>Oncology</i> , <b>2004</b> , 66, 132-7	3.6	10
32	Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. <i>Cancer</i> , <b>2004</b> , 100, 279-87	6.4	122
31	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. <i>Annals of Oncology</i> , <b>2002</b> , 13, 614-21	10.3	85
30	Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. <i>Annals of Oncology</i> , <b>2002</b> , 13, 299-307	10.3	100
29	Resection versus transplantation for liver metastases from neuroendocrine tumors. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 1537-9	1.1	80
28	The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2000</b> , 75, 65-73	5.1	6
27	Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 45, 285-9	4	43
26	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. <i>Cancer</i> , <b>1999</b> , 86, 858-65	6.4	210
25	FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 1149-54	8.7	7

24	5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. <i>Cancer</i> , <b>1998</b> , 83, 372-8	6.4	121
23	Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. <i>Cancer</i> , <b>1998</b> , 83, 1136-41	6.4	10
22	Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 687-90	7.5	11
21	Doxifluridine: Previous Experience and new Developments in the Treatment of Colorectal Cancer. <i>Tumori</i> , <b>1997</b> , 83, 87-89	1.7	1
20	Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. <i>Oncology</i> , <b>1996</b> , 53, 54-7	3.6	13
19	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 2546-51	2.2	117
18	Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. <i>Cancer</i> , <b>1996</b> , 77, 402-8	6.4	224
17	Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. <i>Cancer</i> , <b>1996</b> , 78, 2087-93	6.4	11
16	Feasibility of Intraportal Chemotherapy with Fluorouracil and Folinic Acid Immediately after Hepatic Resection for Colorectal Metastases. <i>Tumori</i> , <b>1995</b> , 81, 96-101	1.7	2
15	Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. <i>Oncology</i> , <b>1995</b> , 52, 41-4	3.6	19
14	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 2613-9	2.2	39
13	Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. <i>European Journal of Cancer</i> , <b>1995</b> , 31A, 2426-7	7.5	3
12	A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. <i>Annals of Oncology</i> , <b>1995</b> , 6, 77-9	10.3	74
11	Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. <i>British Journal of Cancer</i> , <b>1995</b> , 71, 1111-4	8.7	14
10	Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. <i>British Journal of Cancer</i> , <b>1995</b> , 72, 1007-12	8.7	66
9	Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. <i>Transplant International</i> , <b>1994</b> , 7 Suppl 1, S409-11	3	4
8	Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 596-600	7.5	12
7	Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. <i>European Journal of Cancer</i> , <b>1993</b> , 29A, 1215-6	7.5	3

6	Treatment of carcinoid syndrome with recombinant interferon alpha-2a. <i>Acta Oncologica</i> , <b>1993</b> , 32, 235-8	3.2	33
5	Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. <i>Acta Oncologica</i> , <b>1993</b> , 32, 245-50	3.2	17
4	Medical Treatment of Neuroendocrine Tumors. <i>Tumori</i> , <b>1993</b> , 79, 380-388	1.7	11
3	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. <i>Cancer</i> , <b>1993</b> , 72, 3099-105	6.4	107
2	Well-Differentiated Neuroendocrine Carcinoma of the Lung: A Case Report. <i>Tumori</i> , <b>1991</b> , 77, 282-284	1.7	1
1	Ramucirumab as First-Line Therapy in Combination with Cisplatin and Fluoropyrimidine in Patients with Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINFALL): A Global, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial. <i>SSRN Electronic Journal</i> ,	1	2